Avalo CMO exercises options, sells 108,234 shares
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported option exercises and related share sales in Avalo Therapeutics, Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported option exercises and related share sales in Avalo Therapeutics, Inc. common stock. On May 5–6, 2026, she exercised stock options covering 108,234 shares at strike prices of $8.04 and $12.65 per share and sold 108,234 shares in open-market transactions.
The sales occurred at prices ranging from $16.00 to about $22.88, executed in multiple trades. According to a footnote, all transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Insider Trade Summary 10b5-1
Exercise and Sale: 108,234 shares ($996K approx. pre-tax spread)
Exercise and Sale
14 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
108,234 shs ($2.23M)
Approx. gross sale proceeds
$2.23M
Approx. exercise cost
$1.23M
Approx. pre-tax spread
$996K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 77,905 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 28,650 | $0.00 | $0.00 |
| Exercise | Common Stock | 77,905 | $12.65 | $985K |
| Exercise | Common Stock | 28,650 | $8.04 | $230K |
| Sale | Common Stock | 27,538 | $18.0262 | $496K |
| Sale | Common Stock | 5,000 | $19.6502 | $98K |
| Sale | Common Stock | 44,944 | $21.1968 | $953K |
| Sale | Common Stock | 19,015 | $22.406 | $426K |
| Sale | Common Stock | 10,058 | $22.88 | $230K |
| Exercise | Stock Option (Right to Buy) | 1,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 679 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,000 | $12.65 | $13K |
| Exercise | Common Stock | 679 | $8.04 | $5K |
| Sale | Common Stock | 1,679 | $16.00 | $27K |
Holdings After Transaction:
Stock Option (Right to Buy) — 250,625 contracts (Direct);
Common Stock — 3,622 shares (Direct)
Footnotes (7)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3. The reported securities were sold in multiple transactions at prices ranging from $19.08 to $19.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F4. The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F5. The reported securities were sold in multiple transactions at prices ranging from $21.83 to $22.80. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F6. The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
- F7. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 108,234 shares
Shares exercised: 108,234 shares
Sale price range: $16.00 to about $22.88 per share
+5 more
8 metrics
Shares sold
108,234 shares
Total open-market sales reported in Form 4
Shares exercised
108,234 shares
Stock options converted to common stock
Sale price range
$16.00 to about $22.88 per share
Reported common stock sale prices
Option strike price 1
$8.04 per share
Exercise price for one stock option grant
Option strike price 2
$12.65 per share
Exercise price for another stock option grant
10b5-1 plan adoption date
November 13, 2025
Date CMO adopted trading plan for these transactions
Option expiration 1
January 28, 2035
Expiration date for $8.04 strike option
Option expiration 2
July 15, 2034
Expiration date for $12.65 strike option
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), derivative exercise/conversion, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with underlying common stock"
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for M-coded transactions"
open-market sale financial
"transaction_action: "open-market sale" for S-coded transactions"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Avalo Therapeutics (AVTX) report for Doyle Mittie?
Avalo Therapeutics Chief Medical Officer Doyle Mittie exercised stock options for 108,234 shares and sold 108,234 common shares in open-market trades. The transactions occurred on May 5–6, 2026 as part of a disclosed Rule 10b5-1 trading plan.
Were the Avalo Therapeutics (AVTX) insider trades under a Rule 10b5-1 plan?
Yes. A footnote states all reported transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Such plans pre-schedule trades, which generally makes the timing appear more routine and less reflective of short-term market views.
What stock options did the Avalo Therapeutics (AVTX) CMO exercise in this Form 4?
The CMO exercised stock options with exercise prices of $8.04 and $12.65 per share, covering a total of 108,234 underlying common shares. Related footnotes describe vesting schedules with 25% vesting on specified dates, followed by monthly vesting over three years.
What does the Form 4 reveal about Avalo Therapeutics (AVTX) option vesting terms?
Footnotes explain certain stock options vest 25% on July 15, 2025 or January 28, 2026, with the remaining 75% vesting in equal monthly installments over three years. Vesting remains contingent on the reporting person’s continued service through each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
